Randy Hill Appointed to Vasomedical Board of Directors

            Randy Hill Appointed to Vasomedical Board of Directors

PR Newswire

WESTBURY, N.Y., April 17, 2013

WESTBURY, N.Y., April 17, 2013 /PRNewswire/ --Vasomedical, Inc. (OTC BB:
VASO) (the "Company"), a diversified medical technology company specializing
in the design, manufacture and sale of medical devices and in the domestic
sale of diagnostic imaging products, today announced the appointment of Mr.
Randy Hill to the Board of Directors effective immediately. 

Mr. Hill, 66, a veteran of the medical device industry, is currently Senior
Vice President of Vasomedical and Chief Executive Officer of Vaso Diagnostics,
Inc. d/b/a/ VasoHealthcare, a wholly owned subsidiary of Vasomedical, Inc.
Prior to joining Vasomedical in July 2012, Mr. Hill held several senior
leadership positions at major medical device and technology companies. Mr.
Hill was, until May 2011, interim Chief Executive Officer of Siemens
Healthcare USA, the U.S. organization of the healthcare sector of Siemens AG,
a German multinational conglomerate. At Siemens Healthcare USA, he was
responsible for sales, marketing, service, and logistics across the Siemens
Healthcare portfolio, including medical imaging equipment, healthcare
information technology and medical therapy. For several years prior to that,
Mr. Hill was Chief Operating Officer of Siemens Healthcare USA, responsible
for setting and implementing national strategies to sell Siemens products and
services, and achieving synchronization across Siemens Healthcare's U.S.
Business Management and Solutions Implementation teams.

As a recognized leader in the medical imaging business, Mr. Hill is also
former Chair of the Board of Medical Imaging & Technology Alliance (MITA), a
leading organization and collective voice of medical imaging equipment
manufacturers, innovators, and product developers. MITA represents companies
whose sales comprise more than 90 percent of the global market for medical
imaging technology.

"Randy has done an outstanding job in leading VasoHealthcare and we believe he
will be an invaluable asset to the Board with his in-depth knowledge of the
diagnostic imaging business and broad understanding of the medical device
industry," commented Dr. Jun Ma, President and CEO of Vasomedical. "We are
excited to have Randy join the Board and participate in the strategic planning
and future of the entire company."

"I am honored to join the Vasomedical Board of Directors and take an even more
active role in helping plan the future strategy for the Company's overall
business," said Mr. Hill. "I am eager to hit the ground running and share my
industry expertise with the group. I look forward to working with my fellow
Board members in advancing the interests and growth of the Company."

Mr. Hill will stand for election as a Class 1 director at the 2013 Annual
Meeting of Stockholders.

About Vasomedical

Vasomedical, Inc. is a diversified medical technology company specializing in
the manufacture and sale of medical devices and in the domestic sale of
diagnostic imaging products. The Company's main proprietary products are
EECP^® Therapy systems, the gold standard of ECP treatment. The Company
operates through three wholly owned subsidiaries: VasoSolutions, Vasomedical
Global and VasoHealthcare. VasoSolutions manages and coordinates the design,
manufacture and sales of EECP® Therapy systems, and other medical equipment
operations; Vasomedical Global operates the Company's China-based
subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive
sales representation of GE Healthcare diagnostic imaging products in certain
market segments. Additional information is available on the Company's website
at www.vasomedical.com.

Except for historical information contained in this release, the matters
discussed are forward-looking statements that involve risks and uncertainties.
When used in this release, words such as "anticipates", "believes", "could",
"estimates", "expects", "may", "plans", "potential" and "intends" and similar
expressions, as they relate to the Company or its management, identify
forward-looking statements. Such forward-looking statements are based on the
beliefs of the Company's management, as well as assumptions made by and
information currently available to the Company's management. Among the factors
that could cause actual results to differ materially are the following: the
effect of business and economic conditions; the effect of the dramatic changes
taking place in the healthcare environment; the impact of competitive
procedures and products and their pricing; medical insurance reimbursement
policies; unexpected manufacturing or supplier problems; unforeseen
difficulties and delays in the conduct of clinical trials and other product
development programs; the actions of regulatory authorities and third-party
payers in the United States and overseas; uncertainties about the acceptance
of a novel therapeutic modality by the medical community; continuation of the
GEHC agreement; and the risk factors reported from time to time in the
Company's SEC reports.The Company undertakes no obligation to update
forward-looking statements as a result of future events or developments.

Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250
tfromer@kcsa.com / grussell@kcsa.com

SOURCE Vasomedical, Inc.

Website: http://www.vasomedical.com